Nyxoah S.A.

NASDAQ:NYXH

Medical - Instruments & Supplies

Healthcare
$0.86 +1.25%

+$0.02 today

Market cap
$87.89M
Beta
0.89
P/E (TTM)
-0.7
EPS (TTM)
-$1.99
52W Low $1.26High $8.59

Volume 0.17M

Average 0.22M

NYXH Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Nyxoah S.A.NASDAQ: NYXH

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development dips below year-ago levels

Q1 FY2026 research & development of €8.7M fell 3.6% year over year, behind the +17.3% change in trailing-twelve-month research & development. Sequentially, it fell 19.9% from the prior quarter. Over 3 fiscal years it compounded at +39.2% a year.

Context

  • Research & development amounted to 427.4% of revenue in FY2025, down 331.8 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -3.6% toward the trailing-twelve-month pace of +17.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
€8.7M-19.9% QoQ
Last fiscal yearDec 2025
€42.82M+24.8% YoY
LTMMar 2026
€42.56M+17.3% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-3.6%——
1 year+24.8%——
3-year CAGR+39.2%——
5-year CAGR——
10-year CAGR——

Research & Development history

EUR · from the income statement

Latest · FY2025
42.82M EUR
Year-over-year change
+24.8%
4-year CAGR
+63.8%

Research & Development vs competitors

How NYXH compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +17.3% is the 4th highest of 10, against a peer median of -6.3%.
  • Research & development amounts to 260.8% of revenue for NYXH, versus a peer median of 25.8%.
NYXH Competitors
Research & Development for NYXH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CATXPerspective Therapeutics, Inc.LTM Mar 2026$85.68M USD+76.6%+218.7%13864.6%
IVVDInvivyd, Inc.LTM Mar 2026$58.4M USD-50.0%-40.2%104.5%
TARAProtara Therapeutics, Inc.LTM Mar 2026$46.96M USD+41.8%+36.4%—
OSUROraSure Technologies, Inc.LTM Mar 2026$46.23M USD+68.7%+5.5%40.9%
OABIOmniAb, Inc.LTM Mar 2026$44.75M USD-15.8%-0.4%154.8%
NYXHNyxoah S.A.LTM Mar 2026€42.56M EUR+17.3%+39.2%260.8%
STIMNeuronetics, Inc.LTM Mar 2026$6.33M USD-47.4%-11.0%4.2%
KRMDKORU Medical Systems, Inc.LTM Mar 2026$4.59M USD-6.3%-4.0%10.6%
PREPrenetics Global LimitedLTM Mar 2026$4.57M USD-56.9%-5.0%4.0%
UTMDUtah Medical Products, Inc.LTM Mar 2026$668K USD-5.0%+10.7%1.8%
Peer median (excluding NYXH) —-6.3%-0.4%25.8%

Competitors are the stored peer set for NYXH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue852K3.08M4.35M4.52M10.02M
Cost of Revenue303K1.15M1.66M1.55M3.69M
Gross Profit549K1.93M2.69M2.97M6.33M
Gross Margin64.4%62.7%61.9%65.7%63.1%
Research & Development5.95M15.86M27.66M34.33M42.82M
Selling, General & Admin11.11M18.86M20.65M28.46M46.44M
Operating Expenses26.79M34.43M47.79M61.78M89.27M
Depreciation & Amortization1.66M1.93M2.36M764K4.48M
EBITDA(22.59M)(27.89M)(42.08M)(53.77M)(82.9M)
EBITDA Margin-2651.5%-904.2%-967.8%-1189.2%-827.4%
Operating Income(26.24M)(32.5M)(45.1M)(58.81M)(82.94M)
Operating Margin-3080.0%-1053.8%-1037.3%-1300.8%-827.8%
Interest Income1K372K2.57M2.5M1.83M
Interest Expense386K237K1.21M1.9M1.69M
Other Income / Expenses1.6M2.44M445K2.38M(6.13M)
Income Before Tax(24.64M)(30.06M)(44.66M)(56.43M)(89.08M)
Pre-Tax Margin-2891.9%-974.6%-1027.1%-1248.2%-889.0%
Income Tax Expense2.98M1.17M(1.45M)2.8M1.01M
Net Income(27.62M)(31.23M)(43.21M)(59.24M)(90.09M)
Net Margin-3241.7%-1012.5%-993.8%-1310.2%-899.1%
EPS (Basic)(1.16)(1.21)(1.55)(1.81)(2.37)
EPS (Diluted)(1.16)(1.21)(1.55)(1.81)(2.37)
Weighted Avg Shares23.79M25.82M27.97M32.74M38.11M
Weighted Avg Shares (Diluted)23.79M25.82M27.97M32.74M38.11M

Nyxoah S.A.

NASDAQ:NYXH

Intrinsic Alpha fair value

Locked

Current Price

$0.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.